CGC - Marijuana Stocks Hit by Fresh FDA Warning About CBD
The share prices of several notable marijuana stocks are slumping on a new warning about cannabidiol (CBD) from the U.S. Food and Drug Administration (FDA).
Yesterday the health industry regulator issued a new "consumer update" regarding CBD, the nonpsychoactive ingredient in cannabis that proponents say has medicinal properties.
The FDA sounded a fairly alarming note about the substance. It pointed out that using CBD can result in liver injury, cause significant side effects if used in conjunction with other drugs, and cause drowsiness and mood swings. The regulator emphasized that these effects could occur before a user is aware of them.